Results 1 to 10 of about 6,465 (327)

Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis [PDF]

Medicina
Background and Objectives: Peptide receptor radionuclide therapy (PRRT) using radiopharmaceuticals labelled with Lutetium-177 is currently a therapeutic option for patients with advanced neuroendocrine neoplasms overexpressing somatostatin receptors ...
Alessio Rizzo, Alessio Imperiale, Salvatore Annunziata, Roberto C. Delgado Bolton, Domenico Albano, Francesco Fiz, Arnoldo Piccardo, Marco Cuzzocrea, Gaetano Paone, Giorgio Treglia   +9 more
doaj   +4 more sources

Quality control of actinium-225 and 225Ac-radiopharmaceuticals: Francium-221 to be or not to be? [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Actinium-225 radiopharmaceuticals have drawn great interest in cancer therapy due to their tumor-specific delivery of cytotoxic alpha-particles.
Miguel Toro-Gonzalez, Luke Wheeless, Vijai Kumar Reddy Tangadanchu, Cory Hawkins, Shannon Provo, William Smith, Michael Hommen, Dan DeVries, Jim Harvey, Tyler Drum, Diane S. Abou   +10 more
doaj   +3 more sources

Pathogen-Specific Actinium-225 and Lutetium-177 Labeled Antibodies for Treatment of Biofilm-Associated Implant Infections: Initial In Vivo Proof-of-Concept [PDF]

Antibiotics
Background: the primary challenge with implant infections is the formation of biofilm, which harbors dormant bacteria that reduce the effectiveness of antibiotics and amplify antibiotic resistance, exacerbating the global antimicrobial resistance crisis.
F. Ruben H. A. Nurmohamed, Kevin J. H. Allen, Mackenzie E. Malo, Connor Frank, J. Fred F. Hooning van Duvenbode, Berend van der Wildt, Alex J. Poot, Marnix G. E. H. Lam, Jos A. G. van Strijp, Peter G. J. Nikkels, H. Charles Vogely, Harrie Weinans, Ekaterina Dadachova, Bart C. H. van der Wal   +13 more
doaj   +3 more sources

Alpha Therapy Beyond TOC and TATE—Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3 [PDF]

Pharmaceuticals
Objectives: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) commonly relies on somatostatin receptor subtype 2 (SSTR2) agonists such as DOTA-TOC/TATE, which may show limited efficacy due to high hepatic uptake and therapy ...
Lukas Greifenstein, Marcel Martin, Sarah Stephan, Aleksandr Eismant, Carsten S. Kramer, Christian Landvogt, Corinna Mueller, Frank Rösch, Richard P. Baum   +8 more
doaj   +2 more sources

Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer [PDF]

EJNMMI Research
Background Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) with the alpha-emitter actinium-225 (225Ac) has shown promising activity in metastatic castration-resistant prostate cancer (mCRPC), but its use is limited by
Mariam Amghar, Tobias Rausch, Hilal Özgür, Mareike Roscher, Ulrike Bauder-Wüst, Frank Bruchertseifer, Alfred Morgenstern, Vladimír Beneš, Clemens Kratochwil, Martina Benešová-Schäfer   +9 more
doaj   +2 more sources

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

OncoImmunology, 2019
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity
Ekaterina Dadachova, Mackenzie E Malo, Kevin J H Allen   +2 more
exaly   +2 more sources

[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Targeted Alpha Therapy shows very promising clinical results in a cancer treatment and it should be comparable or better than chemotherapy and β-radionuclide therapy, in terms of efficacy and toxicity.
Michela Aurilio, Aureliana Esposito, Monica Buonanno, Anna Morisco, Costantina Maisto, Stefania Scala, Secondo Lastoria   +6 more
doaj   +2 more sources

High-energy resolution X-ray spectroscopy reveals bonding characteristics of La3+ homologues of actinium radiopharmaceuticals [PDF]

Communications Chemistry
Spectroscopic techniques are essential for accurately probing the electronic structures of coordination compounds and revealing the nature of their chemical bonding.
Harry Ramanantoanina, Bianca Schacherl, Attila Kovács, Michelangelo Tagliavini, Emily Marie Reynolds, Cedric Reitz, Ruwini S. K. Ekanayake, Martin Schäfer, Paul-Valentin von Massow, Jörg Göttlicher, Ralph Steininger, Kathy Dardenne, Maurits W. Haverkort, Martina Benešová-Schäfer, Tonya Vitova   +14 more
doaj   +2 more sources

Studies on the optimal electrodeposition of actinium in alcohol-based electrolytes

Fushe yanjiu yu fushe gongyi xuebao, 2022
To determine the optimal electrodeposition conditions for actinium in a nitric acid/ethanol electrolyte, the 228Ac nuclide was used for electrodeposition experiments in a nitric acid/ethanol electrolyte in this study. First, under a current of 0.1 A, the
XIE Zhongyang, YU Guobing, XU Ping, GONG Ziyue, WEN Deyun, WANG Jinlong, XU Feng, CHEN Zhi   +7 more
doaj   +1 more source

Targeted alpha therapy for glioblastoma

Frontiers in Medicine, 2022
According to the 2021 World Health Organization Classification of Tumors of the Central Nervous System, glioblastoma (GB) is a primary brain tumor and presents with the worst prognosis. Due to its infiltrating characteristic, molecular heterogeneity, and
Jolanta Kunikowska, Alfred Morgenstern, Kacper Pełka, Kacper Pełka, Frank Bruchertseifer, Leszek Królicki   +5 more
doaj   +1 more source